Clearmind Medicine Inc.
CMNDNASDAQHealthcareBiotechnology
Previous close
$1.74
+$0.015 · +0.87%
CMND company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
33
Expensive
Momentum
17
Strong Down
Sentiment
59
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteClearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Adi Zuloff-Shani
- Listed since
- Nov 15, 2022
- Employees
- 4
Market position
Day range
Current $1.74
52-week range
Current $1.74
- Open
- $1.74
- Previous close
- $1.725
- Volume
- 47.14K
- 0.03× average
- Average volume
- 1.71M
- Average daily volume
- Market cap
- 2.58M USD
- Beta
- -1.26
- Market reference 1
- 50-day average
- $2.0994
- -17.12% below average
- 200-day average
- $24.1856
- -92.81% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 402.27M USD
- EV / EBITDA
- -108.21×
- Earnings yield
- -0.95%
- Free cash flow yield
- -1.17%
Profitability & efficiency
- Return on equity
- -323.41%
- Return on assets
- -63.41%
- Return on invested capital
- -190.72%
Financial health
- Current ratio
- 1.22×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 49.36K USD | 51.07K USD | 57.43K USD | 119.62K USD | 2.53K USD |
| Gross profit | −49.36K USD | −51.07K USD | −57.43K USD | −119.62K USD | −2.53K USD |
| Research and development | 2.05M USD | 1.37M USD | 1.53M USD | 4.42M USD | 635.4K USD |
| Selling, general, and administrative | 3.57M USD | 4.32M USD | 4.71M USD | 4.47M USD | 2.98M USD |
| Operating expenses | 5.62M USD | 5.69M USD | 6.24M USD | 8.88M USD | 3.61M USD |
| Interest income | 132.9K USD | 271.22K USD | 59.09K USD | — | — |
| Interest expense | 19.54K USD | 36.16K USD | — | 20.76K USD | — |
| Depreciation and amortization | 49.36K USD | 51.07K USD | 57.43K USD | 119.62K USD | 2.53K USD |
| Operating income | −5.67M USD | −5.74M USD | −6.29M USD | −9M USD | −3.61M USD |
| Net income | −3.86M USD | −5.25M USD | −8.61M USD | −9.93M USD | −3.66M USD |
Company facts updated Aug 24, 2026.
CMND news
CMND peers
ETFs holding CMND
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research CMNDresearch.disclaimer